# Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

> **NCT02205489** · PHASE4 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 58 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** Alemtuzumab GZ402673
- **DRUG:** cetirizine
- **DRUG:** ranitidine
- **DRUG:** methylprednisolone
- **DRUG:** methylprednisolone
- **DRUG:** aciclovir
- **DRUG:** esomeprazole
- **DRUG:** ibuprofen
- **DRUG:** paracetamol

## Key facts

- **NCT ID:** NCT02205489
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02205489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02205489, "Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02205489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*